Does OTC naloxone actually reach more people?
Yes, but the improvement is real yet modest. A 2024 study of 192 North Carolina pharmacies found that same-day naloxone availability without a prescription jumped from 42.2% before OTC sales began to 57.8% after—meaning about 1 in 6 more pharmacies could sell it on the spot [1]. That's a meaningful gain, but it also means over 40% of pharmacies still couldn't provide it same-day, so the policy didn't solve access overnight.
The same study found that the average out-of-pocket cost for cash-paying customers dropped from $90.93 to $62.67—a 31% reduction [1]. Lower cost removes a barrier, especially for people without insurance or who want anonymity. But the price is still high for many, and the study noted that independent pharmacies charged more than chains ($77.59 vs. $57.74 after OTC), and rural/suburban pharmacies charged more than urban ones [1]. So while OTC helped, it didn't erase geographic or pharmacy-type disparities.
Does more access translate to more survivors?
The strongest evidence here says yes: naloxone saves lives when it's actually administered. A Pennsylvania study using 2018–2020 overdose data found that people who received at least one dose of naloxone had 11 times greater odds of surviving an opioid overdose [3]. That's a huge effect, and it directly supports the logic behind expanding access—if more naloxone is in more hands, more overdoses can be reversed.
But the same study also showed that survival rates varied by county, with lower rates in less populated areas [3]. This aligns with the North Carolina finding that rural pharmacies had higher costs and lower availability [1]. So the population-level benefit depends on closing these gaps—otherwise, the people most at risk in underserved areas may not get the drug in time.
What are the caveats—and what else is needed?
OTC approval is necessary but not sufficient, as a 2023 commentary argues [5]. The authors warn that without ensuring a sustainable supply and affordable price, the transition could paradoxically reduce access for the most vulnerable [5]. They also stress that comprehensive distribution programs—like overdose education and naloxone distribution (OEND)—remain vital because they reach people who might not walk into a pharmacy [5].
Data from Massachusetts (2014–2018) show that even with standing orders (which allow pharmacists to dispense without an individual prescription), communities with larger Hispanic populations and rural areas were less likely to dispense any naloxone [2]. This suggests that policy changes alone don't fix inequities; targeted outreach and funding are needed. The same paper found that areas with more buprenorphine treatment (a medication for opioid use disorder) dispensed more naloxone, hinting that integrating naloxone with treatment services can boost reach [2].
Finally, state policies vary widely. A 2022 review of four hard-hit states (Kentucky, Massachusetts, New York, Ohio) found that while all moved toward greater access, they used different mechanisms—some had statewide standing orders, others didn't—and Medicaid coverage differed, with some states imposing quantity limits [4]. This patchwork means that the population-level impact of OTC naloxone will differ by state, and ongoing monitoring is needed to ensure the policy delivers on its promise.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2021 to 2024, 1 from 2024 or later, 5 in Q1 journals, collectively cited 126 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 37 papers retrieved from a database of over 500 million.
Sources used in this answer
Naloxone Availability and Cost After Transition to an Over-the-Counter Product
In a longitudinal secret-shopper study of 192 North Carolina pharmacies, same-day naloxone availability rose from 42.2% to 57.8% and average out-of-pocket cost fell from $90.93 to $62.67 after OTC approval, though costs remained higher at independent and rural/suburban pharmacies.
Broadening access to naloxone: Community predictors of standing order naloxone distribution in Massachusetts
Using pharmacy dispensing data from 70% of Massachusetts retail pharmacies (2014–2018), communities with larger Hispanic populations and rural areas were less likely to dispense any naloxone under standing orders, while areas with more buprenorphine treatment and more overdose deaths dispensed more.
Disparities in opioid overdose survival and naloxone administration in Pennsylvania
Analyzing 2018–2020 Pennsylvania overdose data, individuals who received at least one dose of naloxone had 11 times greater odds of survival, but survival and naloxone administration rates were lower in less populated counties.
The policy landscape for naloxone distribution in four states highly impacted by fatal opioid overdoses
A descriptive policy review of Kentucky, Massachusetts, New York, and Ohio found that naloxone access laws, Medicaid coverage, and community distribution infrastructure varied, with some states using statewide standing orders and others not, and some imposing quantity limits.
Moving Naloxone Over the Counter Is Necessary but Not Sufficient
A commentary argues that OTC naloxone approval is necessary but not sufficient, warning that without ensuring supply, sustainable pricing, and continued support for comprehensive distribution programs, access could be threatened for the most vulnerable.